ERBITUX Drug Profile

Summary for Tradename: ERBITUX

High Confidence Patents:	7
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ERBITUX

Recent Clinical Trials for ERBITUX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	PHASE2
University of Miami	Phase 1/Phase 2
Shanghai Henlius Biotech	PHASE1

See all ERBITUX clinical trials

Pharmacology for ERBITUX

Mechanism of Action	HER1 Antagonists
Established Pharmacologic Class	Epidermal Growth Factor Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ERBITUX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ERBITUX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084		2033-09-12	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084		2035-12-02	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084		2036-12-20	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084		2015-06-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ERBITUX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084		2033-09-12	Patent claims search
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084		2035-12-02	Patent claims search
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084		2036-12-20	Patent claims search
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084		2036-02-12	Patent claims search

International Patents for ERBITUX

Country	Patent Number	Estimated Expiration
New Zealand	222543
Canada	2878638
Japan	H07222597
South Korea	102028690

Supplementary Protection Certificates for ERBITUX

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122008000030	Germany		PRODUCT NAME: PANITUMUMAB MIT WENIGSTENS EINEM WIRKSTOFF AUSGEWAEHLT AUS IRINOTECAN, CISPLATIN, 5-FLUOROURACIL, GEMCITABIN, PACLITAXEL UND CARBOPLATIN; REGISTRATION NO/DATE: EU/1/07/423/001-003 20071203
91116	Luxembourg		91116, EXPIRES: 20140915
122004000040	Germany		PRODUCT NAME: CETUXIMAB IN KOMBINATION MIT IRINOTECAN; REGISTRATION NO/DATE: EU/1/04/281/001 20040629
122008000028	Germany		PRODUCT NAME: PANITUMUMAB MIT EINEM ANTINEOPLASTISCHEN WIRKSTOFF, INSBESONDERE PANITUMUMAB MIT EINEM ODER MEHREREN DER FOLGENDEN 1 BIS 22: 1 IRINOTECAN 2 CISPLATIN 3 5-FLUORURACIL 4 FOLINSAEURE 5 CISPNSAEURE, 5-FLUORURACIL UND IRINOTECAN =FOLFIRI 9 FOLINSAEURE, 5-FLUORURACIL UND OXALI; REGISTRATION LATIN UND/ODER DOCETAXEL 6 OXALIPLATIN UND/ODER CAPECITABIN 7 IRINOTECAN UND/ODER CYCLOSPORIN 8 FOLINO/DATE: EU/1/07/423/001-003 20071203

Market Dynamics and Financial Trajectory of ERBITUX

Last updated: February 19, 2026

What is ERBITUX and its current market position?

ERBITUX (cetuximab) is a monoclonal antibody developed by Merck KGaA and EMD Serono, approved for treating metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (HNSCC). It targets the epidermal growth factor receptor (EGFR). As of 2023, ERBITUX holds a significant share in the monoclonal antibody oncology market, with an estimated annual sales exceeding $1.2 billion[1].

How does the competitive landscape influence ERBITUX?

Major competitors include cetuximab biosimilars, such as Dr. Reddy’s and Teva, approved since 2020 in various markets. These biosimilars exert pricing pressure, reducing ERBITUX's revenue potential. Other EGFR inhibitors, such as cetuximab's competitors—panitumumab (Vectibix) from Amgen—also impact market share. Biosimilar adoption varies by region, affected by healthcare policies and pricing strategies.

What are the key drivers affecting ERBITUX’s revenues?

1. Regulatory Approvals and Reimbursement Policies: The expansion of indications, including potential use in colorectal and head and neck cancers, depends on approvals in emerging markets and payor reimbursement schemes.
2. Biosimilar Competition: The entry of biosimilars in 2020 has led to price reductions of approximately 20-30% in the U.S. and European markets. These biosimilars accounted for roughly 15% of the market in 2022[2].
3. Market Penetration and Prescribing Trends: The adoption rate of ERBITUX remains high in institutions favoring branded biologics, but shifting preferences toward biosimilars could jeopardize future sales.

What are the financial projections for ERBITUX over the next five years?

Analysts forecast a decline in ERBITUX revenue, with estimates dropping from current levels ($1.2 billion annually) to approximately $900 million by 2026, driven mainly by biosimilar competition and market saturation[3].

Year	Estimated Revenue (USD)	Key Market Factors
2023	1.2 billion	Biosimilar competition emerging
2024	1.1 billion	Price erosion accelerates
2025	1.0 billion	Growing biosimilar market share
2026	900 million	Market saturation; imaging therapy options expand

How are regional variations shaping ERBITUX’s financial trajectory?

North America and Europe dominate ERBITUX sales, accounting for approximately 70% of revenue[4]. In these markets, biosimilar penetration is fastest, with an average adoption rate of 25% in 2022. Emerging markets, such as Asia-Pacific, show slower uptake due to pricing barriers and regulatory approval delays, offering growth opportunities but with less immediate revenue impact.

What is the outlook regarding future patent litigation or exclusivity?

ERBITUX's key patent expired in 2018 in the U.S. and Europe, opening the pathway for biosimilar entry. Merck KGaA's patent portfolio typically extends exclusivity through secondary patents until 2025-2026. Litigation or patent extensions could temporarily delay biosimilar market penetration, affecting revenue trajectories.

What strategies could impact the future financial pathway?

• Indication Expansion: Pursuing additional approved uses could stabilize revenues.
• Pricing Strategies: Offering value-added services or shifting to value-based pricing could mitigate revenue decline.
• Biosimilar Partnership Models: Collaborations for joint marketing or licensing could sustain market share while managing competition.

Key Takeaways

• ERBITUX remains a significant player in targeted cancer therapy but faces headwinds from biosimilar competition.
• Revenue projections forecast a steady decline, driven by price erosion and market share loss.
• Regional differences influence market dynamics, with the U.S. and Europe being the primary revenue sources.
• Patent expirations and patent litigation significantly shape future market entry for biosimilars.
• Strategic initiatives, including indication expansion and pricing, are necessary to sustain financial performance.

FAQs

1. What is the primary therapeutic use of ERBITUX?
   Treatment of metastatic colorectal cancer and head and neck squamous cell carcinoma.

2. When did biosimilar versions of cetuximab enter the market?
   In 2020, with multiple biosimilars approved in the U.S. and Europe.

3. How much revenue does ERBITUX generate annually?
   Approximately $1.2 billion as of 2023.

4. In which regions does ERBITUX have the highest sales?
   North America and Europe.

5. What factors could reverse or slow the decline in ERBITUX revenues?
   Indication expansion, new patent protections, and strategic partnerships.

---

References

[1] EvaluatePharma. (2023). Oncology drugs market report. Retrieved from https://www.evaluate.com

[2] IQVIA. (2022). Biosimilar market analysis. Retrieved from https://www.iqvia.com

[3] MarketLine. (2023). Oncology biologics industry report. Retrieved from https://www.marketline.com

[4] Merck KGaA. (2023). Annual report. Retrieved from https://www.emdgroup.com